A Study of SKB518 in Patients With Advanced Solid Tumors

Summary

This is a first-in-human (FIH), phase 1, multicenter, open-label, dose-escalation study of SKB518 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor relapsed/refractory to standard therapies or for which no effective standard therapy is available.

Timeline

Start

2024-07-04

Primary completion

2026-06-30

Completion

2026-06-30

Drugs

Indications